One study demonstrated the feasibility of CRISPR-edited PDCD1 in effect-memory CTLs with melanoma antigen specificity, and clearly demonstrated its superiority in delaying the growth of PD-L1-positive melanoma (122). This evidence concerns the gene CD274 and melanoma.